Clinically approved drugs induced ChAT expression and acetylcholine production in podocytes in vivo, suggesting the pathway could be pharmacologically targeted.

A mini review finds that preclinical evidence links repeated or prolonged sevoflurane exposure during development with ...

Upper face lines are not a single category, and treating them as one is where most disappointment with botulinum toxin begins ...

The anti-inflammatory cytokine IL-35 reverses obesity-impaired vasodilation in mice and human endothelial cells by activating ...

A review of 5 investigational therapies with target action dates in November 2026, spanning neurology, gastroenterology, and oncology.

An ironic development emerging alongside the “Make America Healthy Again” movement is the portrayal of nicotine as a wellness ...

Alto Neuroscience, Inc. pivots to ALTO-207 for treatment-resistant depression; learn risks, catalysts, dilution, and outlook. Click for this ANRO stock update.

People with myasthenia gravis may need to use many different medicines to manage their symptoms. In recent years, a new group of medicines called complement inhibitors have been approved to treat this ...

ALPHA | Overview of Technology◾️What is Neurocrine Biosciences' SciTech?Pharmaceutical technology targeting neurotransmission ...

Researchers have carried out the first single-cell analysis of mitochondrial DNA in a population of brainstem neurons that are particularly vulnerable to degeneration in Parkinson's disease.

A conversation with two leading neurologists share actionable insights on proactive baselining, lifestyle rigor, and sensory ...

Batoclimab, an FcRn-targeting antibody that HanAll Biopharma licensed to Harbour BioMed in 2017, has received marketing approval from China's ...